McLaughlin Melissa
Known title: Chief Human Resources OfficerCIK: 0002127187
Associated companies
Transaction History
| ALNY | ▼ Sell | Open Market | 56 | $18K | 4/6/2026 | View on chart |
| ALNY | ▼ Sell | Open Market | 909 | $300K | 4/6/2026 | View on chart |
| ALNY | ▼ Sell | Open Market | 829 | $274K | 4/6/2026 | View on chart |
| ALNY | ▼ Sell | Open Market | 293 | $97K | 4/6/2026 | View on chart |
| ALNY | ▼ Sell | Open Market | 199 | $66K | 4/6/2026 | View on chart |
| ALNY | ▼ Sell | Open Market | 265 | $84K | 4/2/2026 | View on chart |
| ALNY | ▼ Sell | Open Market | 359 | $114K | 4/2/2026 | View on chart |
| ALNY | ▼ Sell | Open Market | 209 | $67K | 4/2/2026 | View on chart |
| ALNY | ▼ Sell | Open Market | 86 | $27K | 4/2/2026 | View on chart |
| ALNY | ▼ Sell | Open Market | 147 | $47K | 4/2/2026 | View on chart |
| ALNY | ▼ Sell | Open Market | 224 | $72K | 4/2/2026 | View on chart |
| ALNY | ▼ Sell | Open Market | 245 | $79K | 4/2/2026 | View on chart |
| ALNY | ▼ Sell | Open Market | 81 | $26K | 4/2/2026 | View on chart |
| ALNY | ▼ Sell | Open Market | 8 | $3K | 4/2/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Alnylam Q3 Earnings Call Set; Analysts Adjust Targets
Alnylam Pharmaceuticals is preparing to discuss its third-quarter 2026 financial results in an upcoming webcast. Ahead of this event, Citigroup and Wells Fargo maintained their ratings but lowered their price targets to $320 and $253, respectively. These adjustments occur while the stock trades near its 52-week low, reflecting a cautious market stance despite ongoing RNAi commercial momentum.
Alnylam Q3 Earnings Call Set; Analysts Adjust Targets. Alnylam Pharmaceuticals is preparing to discuss its third-quarter 2026 financial results in an upcoming webcast. Ahead of this event, Citigroup and Wells Fargo maintained their ratings but lowered their price targets to $320 and $253, respectively. These adjustments occur while the stock trades near its 52-week low, reflecting a cautious market stance despite ongoing RNAi commercial momentum.